← Back to Unlisted Shares

Pre-IPO

Veeda Clinical Research Limited Unlisted Shares

Diagnostics & Clinical Research Services Indicative dealer quote Off-market transfer

Get quote

Current indicative price ₹420

Source: Unlisted Hub dealing desk Updated 26 Sep 2026, 2:20 am IST

Desk buy price₹390

Desk sell price₹420

Minimum lot1

ISIN: INE01HQ01026
CIN: U73100GJ2004PLC044023

Veeda Clinical Research Limited

₹390 Price per share

Minimum quantity39

Minimum investment₹15,000

We respect your privacy. Your information is safe with us.
Prices are indicative; our desk confirms the final price before any deal.

Filed financials

Veeda Clinical Research Limited financials

₹ crore, from the company's filed statements · 6 years · FY 2019-20 to FY 2024-25

What the numbers show

In FY 2024-25, Veeda Clinical Research Limited reported revenue (standalone) of ₹610 crore, up 57.2% from ₹388 crore in FY 2023-24.

It reported a loss after tax of ₹67 crore.

Over the 5 years from FY 2019-20 to FY 2024-25, revenue grew at a compound rate of 32.2% a year.

At the end of FY 2024-25, net worth stood at ₹855.8 crore against borrowings of ₹406 crore (debt to equity 0.47).

Revenue

₹610 cr

FY 2024-25 ▲ 57.2% increase on the previous year

5-yr CAGR 32.2%

Profit after tax

−₹67 cr

FY 2024-25

Net worth

₹855.8 cr

FY 2024-25 ▼ 19.3% decrease on the previous year

5-yr CAGR 57.7%

Operating cash flow

₹33.5 cr

FY 2024-25 ▼ 42.2% decrease on the previous year

5-yr CAGR 30.1%

Revenue and profit after tax, ₹ crore Revenue Profit after tax

Key ratios · FY 2024-25

Return on equity: −7.8%
Debt to equity: 0.47
EBITDA margin: 20.5%
Net margin: −11.0%
EPS (basic): −₹10.19

Veeda Clinical Research Limited, standalone figures in ₹ crore unless stated. The latest year shows the change on the previous year. "—" means not reported; "n.m." means not meaningful.
Fiscal year	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Revenue	610.0 ▲57.2% on FY 2023-24	388.0	409.0	288.0	196.0	151.0
EBITDA	125.0 ▲135.8% on FY 2023-24	53.0	103.0	62.0	67.0	20.0
EBITDA margin	20.5%	13.7%	25.2%	21.5%	34.2%	13.2%
Profit after tax	−67.0	−0.3	42.0	50.0	63.0	−0.0
Net margin	−11.0%	−0.1%	10.3%	17.4%	32.1%	−0.0%
EPS (₹)	−10.19	−0.04	8.00	9.46	17.60	0.00

Veeda Clinical Research Limited, standalone figures in ₹ crore unless stated. The latest year shows the change on the previous year. "—" means not reported; "n.m." means not meaningful.
Fiscal year	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Net worth	855.8 ▼19.3% on FY 2023-24	1,060.0	462.5	436.6	169.8	87.7
Borrowings	406.0 ▲56.2% on FY 2023-24	260.0	48.0	47.0	24.0	17.0
Total assets	1,863.0 ▼8.7% on FY 2023-24	2,040.2	735.0	677.0	285.0	181.0
Debt to equity	0.47×	0.25×	0.10×	0.11×	0.14×	0.19×
Return on equity	−7.8%	−0.0%	9.1%	11.5%	37.1%	−0.0%

Veeda Clinical Research Limited, standalone figures in ₹ crore unless stated. The latest year shows the change on the previous year. "—" means not reported; "n.m." means not meaningful.
Fiscal year	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Operating cash flow	33.5 ▼42.2% on FY 2023-24	58.0	106.0	36.0	77.0	9.0
Profit after tax	−67.0	−0.3	42.0	50.0	63.0	−0.0
Cash flow to profit	—	—	2.52×	0.72×	1.22×	—

Revenue

₹715.5 cr

FY 2025-26

Profit after tax

−₹14 cr

FY 2025-26

Net worth

₹1,120.4 cr

FY 2025-26

Operating cash flow

₹238.7 cr

FY 2025-26

Revenue and profit after tax, ₹ crore Revenue Profit after tax

Key ratios · FY 2025-26

Return on equity: −1.2%
Debt to equity: 0.38
EBITDA margin: 29.3%
Net margin: −2.0%
EPS (basic): −₹2.10

Veeda Clinical Research Limited, consolidated figures in ₹ crore unless stated. The latest year shows the change on the previous year. "—" means not reported; "n.m." means not meaningful.
Fiscal year	FY 2025-26
Revenue	715.5
EBITDA	209.4
EBITDA margin	29.3%
Profit after tax	−14.0
Net margin	−2.0%
EPS (₹)	−2.10

Veeda Clinical Research Limited, consolidated figures in ₹ crore unless stated. The latest year shows the change on the previous year. "—" means not reported; "n.m." means not meaningful.
Fiscal year	FY 2025-26
Net worth	1,120.4
Borrowings	421.4
Total assets	2,044.4
Debt to equity	0.38×
Return on equity	−1.2%

Veeda Clinical Research Limited, consolidated figures in ₹ crore unless stated. The latest year shows the change on the previous year. "—" means not reported; "n.m." means not meaningful.
Fiscal year	FY 2025-26
Operating cash flow	238.7
Profit after tax	−14.0

Filings & documents

The figures on this page are compiled from the company's filed financial statements. Our desk can share the underlying filings on request.

Figures are compiled from the companies' filed financial statements. They are historical, may be restated, and are not a forecast or recommendation. Check the company's annual report before relying on any figure.

Veeda Clinical Research Limited: common questions

What was Veeda Clinical Research Limited's revenue in FY 2024-25?

Veeda Clinical Research Limited reported revenue of ₹610 crore in FY 2024-25 on a standalone basis, according to its filed financial statements.

Did Veeda Clinical Research Limited make a profit in FY 2024-25?

No. Veeda Clinical Research Limited reported a loss after tax of ₹67 crore in FY 2024-25 on a standalone basis.

What is Veeda Clinical Research Limited's net worth?

Veeda Clinical Research Limited's net worth (share capital plus reserves) was ₹855.8 crore at the end of FY 2024-25.

How much debt does Veeda Clinical Research Limited have?

Veeda Clinical Research Limited reported borrowings of ₹406 crore at the end of FY 2024-25.

How many years of financial data are available for Veeda Clinical Research Limited?

This page shows 6 years of filed figures, from FY 2019-20 to FY 2024-25.

Risk disclosure: Unlisted securities are illiquid, are not traded on a recognised stock exchange and can lose value, including the whole of your capital. The prices shown are indicative dealer quotes for information only, not executable prices, an offer, or investment advice.